At a Glance
- Company: Innovacell Inc.
- Location: Tokyo, Japan (spun from Innsbruck University)
- Deal value: $92M (¥14.17B) from 8.4M shares at ¥1,350
- Focus area: Autologous cell therapies for incontinence
- Next steps: Listing Feb 24, 2026; fund Phase 3 ICEF15
What happened?
Japan-based cell therapy company Innovacell filed for a $92 million (¥14.17 billion) initial public offering on the Tokyo Stock Exchange, aiming to list on 24 February 2026. The offering includes 8.4 million initial shares plus overallotment options, priced at ¥1,350 per share, marking the first biotech IPO in Tokyo since 2024.
Why does it matter?
Innovacell’s listing signals renewed investor appetite for late-stage Japanese biotechs amid a strong Nikkei rally, ending a two-year drought. Funds will advance multi-regional Phase 3 trials for ICEF15, an autologous cell therapy for urge fecal incontinence, addressing a market with limited non-surgical options.
Who’s behind it?
Co-CEOs Colin Lee Novick and Jason Sieger lead Innovacell, spun out from Austria’s Medical University of Innsbruck. Backed by a 2025 $48M Series D, the firm develops sphincter muscle cell therapies for fecal and urinary incontinence, with ICEF15 in Phase 3 and ICES13/ICEF16 advancing.
How was it achieved?
Proceeds primarily fund ICEF15 Phase 3 completion, manufacturing scale-up and commercial prep, plus ICES13 (stress urinary incontinence) and ICEF16 first-in-human trials. Venture debt repayment from European Investment Bank also supported; listing leverages Japan’s regenerative medicine regulatory framework.
What’s next?
Post-IPO, Innovacell targets ICEF15 regulatory milestones, leveraging Japan’s conditional approval pathways for cell therapies. Success could catalyse more Tokyo biotech listings, drawing parallels to Nasdaq’s cell therapy ecosystem.
What are people saying?
Co-CEO Novick: “Clear interest in late-stage biotech… at inflection point.” Sieger: “Tokyo natural fit… lower threshold for visibility.”